Document Detail


The impact of diagnostic immunohistochemistry on patient outcomes.
MedLine Citation:
PMID:  10572716     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Diagnostic immunohistology (DIHC) is a discipline that has been used clinically for at least two decades, but, because of medicolegal encumbrances, it has not been a part of many formal outcomes analyses during that time. Potential applications of this technology with a direct bearing on response to treatment include the accurate identification of infectious organisms, distinction between morphologically-similar undifferentiated tumors, separation of benign and malignant neoplasms, and prognostication of malignancies. The first two of those four roles may indeed have a quantifiable impact on case outcomes, but the last two applications have only questionable value in this specific context. This is an area of medicine in which formal outcomes analysis is greatly needed to help determine future practice patterns.
Authors:
M R Wick; J H Ritter; P E Swanson
Related Documents :
21645976 - Continued benefit to androgen deprivation therapy for prostate cancer patients treated ...
12733856 - A patient with postoperative mercury contamination of the peritoneum.
9197186 - Diffuse malignant pleural mesotheslioma at camc: a retrospective study of 50 patients.
22099876 - Prostate cancer in the senior men from rural areas in east district of china: contempor...
6354426 - Resection alloplasty in the treatment of certain malignant bone tumors.
3667166 - A phase ii study of (2"r)-4'-0-tetrahydropyranyladriamycin (thp) in hematological malig...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Clinics in laboratory medicine     Volume:  19     ISSN:  0272-2712     ISO Abbreviation:  Clin. Lab. Med.     Publication Date:  1999 Dec 
Date Detail:
Created Date:  1999-12-09     Completed Date:  1999-12-09     Revised Date:  2006-03-28    
Medline Journal Info:
Nlm Unique ID:  8100174     Medline TA:  Clin Lab Med     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  797-814, vi     Citation Subset:  IM    
Affiliation:
Robert E. Fechner Laboratory of Surgical Pathology, University of Virginia Medical Center, Charlottesville, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Cost-Benefit Analysis
Humans
Immunohistochemistry / economics,  standards*
Neoplasms / diagnosis*
Outcome Assessment (Health Care)*
Pathology, Clinical / economics,  standards*
Reproducibility of Results

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Cost benefit and outcomes analysis for fine-needle aspiration. Why do we know so little?
Next Document:  The impact of molecular diagnostic tests on patient outcomes.